This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Robinson, S. P. Articles by Jordan, V. C. Search for Related Content PubMed PubMed Citation Articles by Robinson, S. P. Articles by Jordan, V. C.

Reversal of the Antitumor Effects of Tamoxifen by Progesterone in the 7,12-Dimethylbenzanthracene-induced Rat Mammary Carcinoma Model¹

Department of Human Oncology, University of Wisconsin Clinical Cancer Center, Madison, Wisconsin 53792

Coadministration of progesterone (4 mg/day) opposed the antitumor activity of tamoxifen (100 µg/day) in rats bearing 7,12-dimethylbenzanthracene-induced tumors and also partially prevented the inhibition by tamoxifen (50 µg/day started 30 days after 7,12-dimethylbenzanthracene administration) of tumor occurrence even after tamoxifen therapy had been established for 1 or 2 mo. Although prolonged progesterone treatment raised progesterone levels, serum total estrogen levels were not raised above control. The reversal by progesterone of the inhibition of tumor occurrence produced by tamoxifen was blocked by the antiprogestin RU 486. These results demonstrate that progesterone can reverse the tumoristatic action of tamoxifen in the 7,12-dimethylbenzanthracene-induced tumor model and that this may be via a progesterone receptor-mediated mechanism.

¹ This work was supported through the generosity of the Wisconsin Clinical Cancer Center Anderson Fund.

² To whom requests for reprints should be addressed, at Department of Human Oncology, Wisconsin Clinical Cancer Center, 600 Highland Ave., Madison, WI 53792.

Received 5/ 6/87. Revised 7/22/87. Accepted 7/24/87.

This article has been cited by other articles:

				I. Benakanakere, C. Besch-Williford, J. Schnell, S. Brandt, M. R. Ellersieck, A. Molinolo, and S. M. Hyder Natural and Synthetic Progestins Accelerate 7,12-Dimethylbenz[a]Anthracene-Initiated Mammary Tumors and Increase Angiogenesis in Sprague-Dawley Rats. Clin. Cancer Res., July 1, 2006; 12(13): 4062 - 4071. [Abstract] [Full Text] [PDF]

				C. A. Sartorius, D. M.E. Harvell, T. Shen, and K. B. Horwitz Progestins Initiate a Luminal to Myoepithelial Switch in Estrogen-Dependent Human Breast Tumors without Altering Growth Cancer Res., November 1, 2005; 65(21): 9779 - 9788. [Abstract] [Full Text] [PDF]

				O. M. Conneely, J. P. Lydon, F. De Mayo, and B. W. O'Malley Reproductive Functions of the Progesterone Receptor Reproductive Sciences, January 1, 2000; 7(1_suppl): S25 - S32. [Abstract] [PDF]

				J. P. Lydon, G. Ge, F. S. Kittrell, D. Medina, and B. W. O'Malley Murine Mammary Gland Carcinogenesis Is Critically Dependent on Progesterone Receptor Function Cancer Res., September 1, 1999; 59(17): 4276 - 4284. [Abstract] [Full Text] [PDF]

				T. K. Said, O. M. Conneely, D. Medina, B. W. O'Malley, and J. P. Lydon Progesterone, in Addition to Estrogen, Induces Cyclin D1 Expression in the Murine Mammary Epithelial Cell, in Vivo Endocrinology, September 1, 1997; 138(9): 3933 - 3939. [Abstract] [Full Text] [PDF]

				J P Lydon, F J DeMayo, C R Funk, S K Mani, A R Hughes, C A Montgomery, G Shyamala, O M Conneely, and B W O'Malley Mice lacking progesterone receptor exhibit pleiotropic reproductive abnormalities. Genes & Dev., September 15, 1995; 9(18): 2266 - 2278. [Abstract] [PDF]

				B. D. Weiss RU 486: The Progesterone Antagonist Arch Fam Med, January 1, 1993; 2(1): 63 - 69. [Abstract] [PDF]